A Company That Scans Your Body in 60 Minutes to Find Hidden Disease Just Pulled In $700M

Here's the deal: the same Daniel Ek who built Spotify is now scanning your body instead of your playlists. On July 15, 2026, Neko Health — the preventive-health startup he co-founded — announced a $700 million Series C, pushing the company's valuation to roughly $7 billion (about 9.7 trillion won). Just 18 months earlier, at its January 2025 Series B, Neko was valued at $1.7 billion. That's a fourfold jump in a year and a half.

The core idea is a bet against the entire logic of modern medicine. Instead of waiting until you're sick, Neko wants to grab healthy, symptom-free people and run them through a non-invasive, radiation-free full-body scan that flags early signs of heart disease, skin cancer, or pre-diabetes in about 60 minutes. So far more than 100,000 people across the UK and Sweden have been scanned, and 350,000+ are sitting on a waitlist.

And the money has one clear destination: the United States. Neko's first US clinic opens in Manhattan later this year. Ek is aiming this thing at the market with the world's biggest healthcare spend — and, paradoxically, the world's weakest track record on prevention. Let's unpack why the money piled in now, and why the skeptics aren't fully convinced.

The Players — Ek, Nilsonne, and Lightspeed

Start with Daniel Ek. He needs little introduction. In 2006 he co-founded Spotify in Sweden and rewrote the economics of the entire music industry around streaming. Spotify is still a public company worth hundreds of billions, and Ek became a billionaire off it. So why healthcare? In his own framing, he wants to build "a completely new healthcare system designed to keep people healthy" — prevention first, treatment second. The same way he made music cheap and accessible via streaming, he wants to take the expensive, inconvenient health check-up and make it cheap and easy.

Then there's co-founder and CEO Hjalmar Nilsonne. He grew up in a family of doctors but took the engineer's path himself, spending most of his career building technology for the energy transition — a serial founder. He brings both the medical family's sense of the problem and the engineer's instinct for how to solve it. Neko's identity is that it designs and builds its own scanning hardware from scratch, and that's very much a Nilsonne fingerprint.

Neko Health was founded in 2018. But it didn't rush to open doors. It spent four years on R&D and only launched publicly on February 2, 2023, in Stockholm. The delay wasn't hesitation — it was hardware. Rather than buying off-the-shelf CT or MRI machines, Neko built its own sensor system from the ground up, one that sweeps the skin, surface, and blood vessels without any radiation. That's why the runway to launch was so long.

This round was led by Lightspeed Venture Partners and O.G. Venture Partners. Lightspeed is a top-tier Silicon Valley firm behind Snap, Robinhood, and Rubrik, and it publicly framed this deal around the thesis that preventive care is "the future of healthcare." From O.G. Venture Partners, David Ofer is joining Neko's board of directors, subject to regulatory approval.

The investor roster is a headline in itself. Existing backers Atomico, General Catalyst, and Lakestar re-upped, joined by new investors Liberty City Ventures, Positive Sum, and BDT & MSD. On the individual side, the cap table now includes Mark Zuckerberg and Priscilla Chan, Tim Ferriss, Maria Sharapova, will.i.am, and OpenAI. From Silicon Valley moguls to celebrities, basically everyone who spends money on longevity showed up.

What Neko Actually Does — 60 Minutes, Thousands of Sensors, Millions of Data Points

Let's get concrete. A customer walks into a clinic and gets a ~60-minute full-body scan. You undress and step into a circular scanner, where thousands of proprietary sensors sweep your skin, surface, and blood vessels, collecting millions of data points. Because there's no radiation, there's none of the exposure worry that comes with X-ray or CT. On top of that, the clinic runs an on-site micro-blood collection for lab analysis.

What it measures: skin health (moles and lesions), pre-diabetes risk, blood abnormalities, and risk factors for metabolic syndrome, stroke, and heart attack. When the scan is done, you get results within minutes and a consultation with a medical professional. Neko recently upgraded to a second generation of hardware — devices called Derma-2, Echo-2, and Spectrum-2 — covering skin, cardiac/blood flow, and optical spectrum respectively.

Price? It's £299 (about $380) in the UK and 2,750 SEK (about $290) in Sweden. US pricing isn't locked yet, but the company says it will be "commensurate with the UK costs." Set against typical US medical check-up prices, that's aggressively cheap. This is Ek's Spotify move again — take a premium service and drag the price down to something the mass market can stomach.

The numbers that really catch the eye are the retention stats. Per the company, 75% of members pre-pay for the next year's annual scan before they even leave their first appointment. And three out of four members whose earlier scans flagged severe or life-threatening anomalies had those conditions under control or were in good health by their next scan. Neko also reports statistically significant improvement across five of seven core biomarkers. To be honest, though, these are all company-reported figures and haven't yet been independently verified — worth flagging plainly.

Item Detail
Announced July 15, 2026
Round Series C, $700M (~9,700억 won)
Valuation ~$7B (4x the Series B)
Prior round Jan 2025 Series B, $260M / ~$1.7B valuation
Lead investors Lightspeed VP + O.G. Venture Partners (co-lead)
New investors Liberty City Ventures, Positive Sum, BDT & MSD
Angels Zuckerberg & Chan, Tim Ferriss, Sharapova, will.i.am, OpenAI
Scan spec 60 min · non-invasive · thousands of sensors · millions of data points + blood draw
Price £299 (UK) / 2,750 SEK (Sweden) / US "commensurate with UK"
Scans to date 100,000+ · waitlist 350,000+
US launch First clinic in Manhattan, H2 2026

What Each Side Gets Out of It

Neko Health gets the obvious thing — $700M in dry powder — plus something arguably more valuable: a mandate to enter the US. It's taking a model validated in Europe into the world's biggest healthcare market, and a 4x valuation jump signals that investors think the European experiment is done and the expansion phase has begun. Because Neko manufactures its own hardware, standing up a single clinic is capital-intensive; this money means it can build a proper Manhattan flagship.

Lightspeed and O.G. get an early seat on the frontrunner in a giant market with no crowned winner yet. Healthcare in the US alone is a $4-trillion-plus annual spend, and almost all of it is money spent after people get sick. Whoever captures the front end — the before you get sick — is chasing an enormous pie. From a VC lens, paying up at a 4x valuation is a defensible bet on owning that front end.

The individual investors — Zuckerberg, Tim Ferriss, OpenAI — get more than a return. Most of them are totemic figures in the longevity community. Putting their names on Neko is itself a piece of marketing that ties their brand to the prevention trend. OpenAI's presence is especially symbolic: it signals they want a foot in how AI interprets medical data.

Customers get, in theory, the peace of mind of catching disease before symptoms appear. Concretely, Calm founder Alex Tew has publicly said a Neko scan detected a malignant mole on his back that he then had removed: "I'm grateful to Neko for helping me discover this — I'm not sure how I would have otherwise." Each story like that is this company's most powerful marketing.

Precedents — The Wins and the Wrecks

Preventive scanning isn't a new idea, and its history is a warning. In the early 2000s, the US went through a whole-body CT scan craze. Clinics popped up everywhere selling "scan yourself even without symptoms." It was a disaster. Between the radiation exposure and a flood of false positives, healthy people ended up getting unnecessary biopsies and surgeries. The FDA and the medical establishment eventually declared that whole-body scans are not recommended for asymptomatic people. That's the historical shadow Neko has to step out from under.

There are success stories too. In the wake of the Theranos collapse, the companies that shone were the ones selling prevention and diagnostics backed by real technology. GRAIL, with its early cancer-detection blood test, drew big capital and partnerships despite controversy, and a wave of continuous-glucose-monitor (CGM) wellness startups went mainstream. The through-line is verifiable clinical data. That's exactly why Neko keeps waving numbers like "75%" and "three in four" — to avoid repeating the whole-body-CT wreck, it has to prove itself with data.

Another useful lens is Ek's own Spotify playbook. When music was polarized between "illegal downloads" and "expensive CDs," Spotify punched through the middle with cheap, convenient, legal streaming. Ek is going for the same move in healthcare. Between a pricey full work-up and skipping check-ups entirely, he wants to create a new category: a cheap, fast, radiation-free annual scan. If it lands, it could be a Spotify-scale disruption.

But the failure risk deserves honesty too. Healthcare is a regulated industry. Spotify just had to clear music licensing; healthcare means different regulations, insurance systems, and medical laws in every country. The US is especially thorny — FDA clearance, state-by-state medical licensing, and insurance coverage are all tangled together. Working in Europe is no guarantee it works the same way in America.

How Rivals Counter-Play

So how do competitors respond to Neko's arrival? The most direct threat comes from US longevity and executive-health clinics. Companies like Function Health and Superpower already sell "100+ biomarker blood panels" on a subscription model. They don't have hardware scanners, but they penetrate the US market far more lightly and quickly. While Neko builds a physical Manhattan clinic, they can scale with at-home blood-draw kits.

The second threat is big-tech wearables like Apple and Samsung. The Apple Watch already does ECG, blood oxygen, and atrial-fibrillation detection, and Apple keeps nudging health data into clinical territory. Neko's own move to add Apple Health data integration is a tacit acknowledgment of this trend. If Apple can flag risk through continuous monitoring without a once-a-year clinic visit, it's an open question how differentiated Neko's 60-minute scan stays.

The third threat is the incumbent hospital and check-up chains. US institutions like the Mayo Clinic and Cleveland Clinic already sell high-priced "executive physicals," and they come with brand trust and insurance networks already built. Even if Neko pushes "cheaper and more convenient," breaking the consumer belief that "when you're actually sick you go to a big hospital" is a separate fight.

The decisive variable in this counter-play is regulation and trust. If rivals frame scanning asymptomatic people as overdiagnosis, Neko has to defend. Conversely, if Neko proves with its own clinical data that "we actually catch disease early and minimize false positives," it flips the frame. Ultimately this market won't be won on marketing — it'll be won by whoever stacks up verifiable results first.

So What Actually Changes

If you're a developer or engineer, Neko is a fascinating case of hardware + AI + health data converging. A pipeline that pulls millions of data points from proprietary sensors and interprets them with AI shows the kind of moat you can't build with software alone in healthtech. OpenAI joining as an investor reads as a signal that the "medical-data interpretation model" game is heating up.

If you're an investor, the question is how to read a 4x valuation jump. Preventive medicine is a giant market with no winner yet, so premiums attach easily. But given the regulatory risk and the whole-body-scan overdiagnosis history, watch the first-year US results and any FDA-related progress closely. The valuation figure is as of announcement, and a US stumble could reset it.

If you're in the healthcare industry, this is a signal that the front-end "prevention" market is opening up in earnest. Insurers, employer benefits, and wellness programs will start figuring out how to bolt on Neko-style preventive scans. Conversely, treatment-centric hospitals should feel the tension of losing the front end to a startup.

If you're a regular user, not much changes today. The first US clinic is a single Manhattan location, and the price still lands in the hundreds of dollars. But if the idea of "getting scanned before you're sick" goes mainstream, an annual health scan in your neighborhood could feel normal within a few years. Right now it's early adopters and the affluent — but Ek's real play, as always, is mass adoption.

🥄 Three Things You're Probably Wondering

— So what does this mean for me? Right now it's a Manhattan, UK, and Sweden story, so the direct impact is small. But if a "scan yourself once a year even without symptoms" culture takes hold, a similar service could reach your area within a few years. For now, just watch and know the concept.

— Does this really catch disease, or is it overdiagnosis? The company touts figures like "three in four managed" and "5 of 7 biomarkers improved," but those are self-reported and not yet independently verified. Given how the whole-body CT craze collapsed under false positives, the medical field is cautious. Real validation will need US clinical and regulatory data to accumulate — too early to call.

— Is a $7B valuation a bubble? A 4x jump in 18 months is undeniably aggressive. The premium comes from a big market with no winner, but whether the first US year justifies it is the crux. If it mass-adopts Spotify-style, it's cheap; if regulation blocks it, it's expensive. Call it 50/50 for now.

Sources

Numbers and criteria are as of announcement and may change. Investment calls are yours to make!